BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 20849855)

  • 1. Pathogenesis of cholestatic liver disease and therapeutic approaches.
    Hirschfield GM; Heathcote EJ; Gershwin ME
    Gastroenterology; 2010 Nov; 139(5):1481-96. PubMed ID: 20849855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G; Beuers U
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
    Silveira MG; Lindor KD
    Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Primary biliary cirrhosis: therapeutic options].
    Abenavoli L
    Recenti Prog Med; 2009 Sep; 100(9):417-23. PubMed ID: 19886235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutical indications of ursodeoxycholic acid.
    Copaci I; Micu L; Iliescu L; Voiculescu M
    Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular mechanisms of bile formation and cholestatic diseases].
    Poupon R
    Bull Acad Natl Med; 2003; 187(7):1261-74; discussion 1274-6. PubMed ID: 15146603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cholestatic liver diseases].
    Reichel C; Meier-Abt PJ
    Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
    Beuers U
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of cholestatic liver diseases].
    Gatzen M; Pausch J
    Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we treat cholestatic liver disease with cholesterol synthesis inhibitors?
    Schmidt HH; Manns MP
    Am J Gastroenterol; 1996 Feb; 91(2):406-7. PubMed ID: 8607528
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of cholestatic liver diseases].
    Karvonen AL
    Duodecim; 2003; 119(6):533-9. PubMed ID: 12708340
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy.
    Lazaridis KN; Talwalkar JA
    J Clin Gastroenterol; 2007; 41(5):494-500. PubMed ID: 17450033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid.
    Tromm A; May B; Klein CG; Klein R; Fisseler-Eckhoff A; Griga T
    Hepatogastroenterology; 2005; 52(63):753-6. PubMed ID: 15966198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cholestasis: therapeutic options].
    Beuers U; Oswald M
    Ther Umsch; 1998 Feb; 55(2):97-103. PubMed ID: 9545851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of autoimmune and cholestatic liver disorders.
    Krok KL; Munoz SJ
    Clin Liver Dis; 2009 May; 13(2):295-316. PubMed ID: 19442920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the therapy of cholestatic liver disease.
    Roda E; Parini P; Bazzoli F; Mazzella G; Festi D; Aldini R
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():53-5. PubMed ID: 1577396
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment with immunosuppressives in patients with primary biliary cirrhosis who fail to respond to ursodiol.
    Kaplan MM; Poupon R
    Hepatology; 2009 Aug; 50(2):652. PubMed ID: 19309721
    [No Abstract]   [Full Text] [Related]  

  • 20. [Interview: questions to Professor Raoul Poupon].
    Poupon R
    Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 1):333-7. PubMed ID: 12700521
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.